The First Food and Drug Administration-Indicated Drug for Postpartum Depression-Brexanolone

Katherine L Wisner^{1

2}, Catherine S Stika², Jody D Ciolino³

Affiliations

¹ Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Comment

Katherine L Wisner et al. JAMA Psychiatry. 2019.

. 2019 Oct 1;76(10):1001-1002.

doi: 10.1001/jamapsychiatry.2019.1546.

Katherine L Wisner^{1

2}, Catherine S Stika², Jody D Ciolino³

¹ Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

No abstract available

Comment on

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S. Meltzer-Brody S, et al. Lancet. 2018 Sep 22;392(10152):1058-1070. doi: 10.1016/S0140-6736(18)31551-4. Epub 2018 Aug 31. Lancet. 2018. PMID: 30177236 Clinical Trial.